Did Spotlighting a Rare Potential Vaccine Side Effect Put More at Risk?

A simple message to calm patients’ fears: “It’s a great thing that they have paused it, and this is science at work.” Our own Maulik Joshi, president and CEO, contributed to The New York Times article on the impact of pausing the J&J COVID-19 vaccine following the recommendation of the CDC/FDA Tuesday, April 13: